ResMed Inc. (RSMDF)
OTCMKTS · Delayed Price · Currency is USD
25.85
-0.31 (-1.17%)
Oct 31, 2025, 4:00 PM EDT
ResMed Revenue
ResMed had revenue of $1.34B in the quarter ending September 30, 2025, with 9.07% growth. This brings the company's revenue in the last twelve months to $5.26B, up 9.36% year-over-year. In the fiscal year ending June 30, 2025, ResMed had annual revenue of $5.15B with 9.84% growth.
Revenue (ttm)
5.26B
Revenue Growth
+9.36%
P/S Ratio
6.85
Revenue / Employee
495.98K
Employees
10,600
Market Cap
36.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.15B | 461.03M | 9.84% |
| Jun 30, 2024 | 4.69B | 462.30M | 10.95% |
| Jun 30, 2023 | 4.22B | 644.87M | 18.02% |
| Jun 30, 2022 | 3.58B | 381.30M | 11.93% |
| Jun 30, 2021 | 3.20B | 239.81M | 8.11% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
ResMed News
- 2 days ago - RMD: RBC Capital Raises Price Target, Maintains Outperform Rating | RMD Stock News - GuruFocus
- 2 days ago - Keybanc Analyst Raises ResMed (RMD) Price Target to $299 | RMD Stock News - GuruFocus
- 2 days ago - Mizuho Maintains 'Outperform' for RMD but Lowers Price Target | RMD Stock News - GuruFocus
- 2 days ago - These Analysts Revise Their Forecasts On ResMed Following Q1 Results - Benzinga
- 2 days ago - These Analysts Revise Their Forecasts On ResMed Following Q1 Results - Benzinga
- 2 days ago - ResMed declares $0.60 dividend - Seeking Alpha
- 2 days ago - Resmed Stock Up on Q1 Earnings & Revenue Beat, Margins Expand - Nasdaq
- 2 days ago - ResMed Inc. 2026 Q1 - Results - Earnings Call Presentation - Seeking Alpha